35777-58-3

Upstream product

• 60915-86-8 1-(O²,O³-isopropylidene-β-D-ribofuranosyl)-6,7-diphenyl-1H-pteridine-2,4-dione 

Downstream Products

• 60981-23-9 (7aS)-8c-hydroxy-9t-hydroxymethyl-2,3-diphenyl-(7ar,10ac)-7a,8,9,10a-tetrahydro-furo[2',3':4,5]oxazolo[3,2-a]pteridin-5-one 
• 60981-26-2 (7aS)-8c-acetoxy-9t-acetoxymethyl-2,3-diphenyl-(7ar,10ac)-7a,8,9,10a-tetrahydro-furo[2',3':4,5]oxazolo[3,2-a]pteridin-5-one 

Relevant academic research and scientific papers

Novel and facil synthesis and evaluation of antitumor activities of 6,7-bisaryl-1-(β-D-ribofuranosyl)pteridine-2,4(1H,3H)-diones

Novel 6,7-bisaryl-1-(β-D-ribofuranosyl)pteridine-2,4(1H,3H)-dione derivatives were synthesized by condensation of 5,6-diamino-2′,3′-O-isopropylideneuridine, which was derived from uridine, with an appropriate α,β-diketone, followed by acidic hydrolysis allowing removal of the isopropylidene group of the sugar moiety as a protecting group. Moreover, several N-3 alkyl derivatives of the 6,7-bisaryl-1-(β-D-ribofuranosyl)pteridine-2,4(1H,3H)-diones were obtained by alkylation of the 6,7-bisaryl-1-(2′,3′-O-isopropylidene-β-D-ribofuranosyl)pteridine-2,4(1H,3H)-diones with alkyl halides and by their acidic hydrolysis for deprotection. The antitumor activities of all synthesized compounds against CCRF-HSB-2 and KB cell lines were also investigated in vitro and some of the compounds showed prospective antitumor activities.